Trials / Conditions / Borderline Resectable Carcinoma
Borderline Resectable Carcinoma
3 registered clinical trials studyying Borderline Resectable Carcinoma — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable NCT07339488 | Chuangzhen Chen | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage NCT06998719 | Bi Nan | Phase 2 |
| Withdrawn | Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma NCT06017297 | Georgetown University | Phase 2 |